RETA Stock News

Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum i

It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe dise

CPMG Inc (Trades, Portfolio), a prominent investment firm, recently expanded its portfolio with the acquisition of a substantial number of shares in Reata Pharmaceuticals Inc. This article provides an

Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.

Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.

Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets.

Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma company for $7.3 billion. Why is Biogen making this

Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That deal has Biogen offering to buy shares of RETA stock

Biogen Inc (NASDAQ:BIIB) said it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion in cash as it bulks up its neuromuscular and rare disease portfolio. Shares of Reata shot up 52% to

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.

Biogen Inc. BIIB, -0.93% said Friday it has agreed to acquire Reata Pharmaceuticals Inc. RETA, +2.32% for $7.3 billion in cash. Reata “has made significant advancements developing therapeutics that

Vertex Pharmaceuticals' strong pipeline is positioning the company for the future. Viking Therapeutics' stock is soaring as the market anticipates its candidate drugs hitting the marketplace.

Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further s